Navigation Links
Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Date:1/26/2009

ROCKVILLE, Md., Jan. 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that all equipment in its new Good Manufacturing Practice ("GMP") Pilot Plant to manufacture pandemic and seasonal influenza vaccine clinical supplies and commercial batches at a 1,000 liter scale are installed and ready for operations supporting scale-up and validation.

The project was initiated in December 2007. The facility demolition, construction and initial qualification were completed in 120 days and were announced with a ribbon cutting in May 2008. The original design by Jacobs Engineering (Conshohocken, PA), which included multiple Wave bioreactors for production of VLPs, has been modified to include stirred reactors based on the potential for enhanced production yield. The stirred reactors, which utilize disposable liners in keeping with the desire to maintain a disposable manufacturing process, were received September 2008 and are now installed in the facility.

The facility is expected to be capable of producing 2-3 million doses of monovalent pandemic influenza vaccine per week at 15 mcg HA/dose (50 - 75 M doses in 6 months) once scale-up and validation are complete. Likewise, the facility can support up to 20 - 25 million doses of trivalent influenza vaccine in six months. The facility is GMP compliant and includes a total of 10,000 square feet of production and support space. The facility also includes media and reagent preparation space and equipment for production of vaccine for clinical trials. Large-scale commercial production, media, reagent and filling of bulk vaccines are planned to be outsourced.

The total cost of the project, including demolition, construction, and installation of laboratory and production equipment, was approximately $5 million. The facility had existing me
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
2. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
3. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
4. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
5. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
6. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
7. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
8. Novavax CEO to Present at BIO Investor Forum 2008
9. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
10. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
11. Novavax Announces Closing of $18 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, ... peptides that are used solely in scientific experiments, is ... successful years in business, Maxim Peptide, which was created ... launched a new and updated website that now features ... section has been updated with fascinating articles about peptide ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Pharmaceuticals, Inc., a,vertically integrated cGMP contract development ... Wood as Vice President, Business,Development. Ms. Wood ... including guiding Stason,s global business development,activities. Ms. ... experience in,sales, marketing, business and strategic planning, ...
... British Columbia researchers has developed a technique that controls ... superconductors, a procedure considered impossible for the past two ... the team deposited potassium atoms onto the surface of ... the scientists to continuously manipulate the number of electrons ...
... for Metabolic and Bariatric Surgery ... ... USGI Medical Inc. (USGI),announced today that leading experts presented clinical evidence ... an incisionless technique to reduce the size of the,gastric pouch and ...
Cached Biology Technology:Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development 2UBC physicists develop 'impossible' technique to study and develop superconductors 2Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass 2
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... body's molecules controls the trafficking of T cells through the ... -- a crucial response that sometimes goes awry, attacking the ... control system -- composed of a fat-like compound called S1P ... cells from launching harmful reactions. But when the S1P traffic ...
... gene mutation that identifies the lung cancer patients most likely ... with a response to the drug cetuximab (Erbitux), according to ... the Journal of the National Cancer Institute. Both ... , Some patients with non?small-cell lung cancer (NSCLC) have mutant ...
... evidence that olfaction is uniquely a "dual" sense, in that ... arrives through the nose rather than the mouth. In the ... that the smell of chocolate activated different brain regions according ... through the mouth or through the nose. , In a ...
Cached Biology News:Discovery of T-cell 'traffic control' boosts new drug promise 2Discovery of T-cell 'traffic control' boosts new drug promise 3Discovery of T-cell 'traffic control' boosts new drug promise 4Treatments have same target, different responses for lung cancer patients with genetic mutation 2Nose odors and mouth odors: The brain distinguishes 2Nose odors and mouth odors: The brain distinguishes 3
b-Catenin (pSer675), phospho-specific...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
PKC (pSer345), phospho-specific...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Biology Products: